Abstract:OBJECTIVE:To investigate the effect of dendritic cells (DCs) pulsed by oligonucleotide containing "un-methylated cytimidine-phosphodiester bond-guanylic acid" motif (CpG ODN) on ovarian carcinoma cells. METHODS:Dendritic cells were isolated form the peripheral monocytes and co-incubated with synthesized CpG2006, CAI125, important epithelial ovarian cancer-associated antigen, or CpG ODN + CA125 for 72 h. Flow cytometry (FC) was used to detect the expression of CD(1alpha), CD(63), CD(86), and human leucocyte antigen-DR (HLA-DR) on the cell surface. ELISA was used to detect the IL-12 level in the supernatant. T cells were obtained from the DCs. The suspensions of different groups of pulsed DCs were co-incubated with T cells. Mixed lymphocyte reaction (MLR) was used to detect the proliferating activity of the T cells. Ovarian carcinoma cells of the line OVCAR-3 were added into the culture fluid of T cells with different effector-target ratios, and then unpulsed DCs, CpG ODN-pulsed DCs, CpG ODN + CA125-pulsed DCs, and CA125-pulsed DCs were added respectively. MTT colorimetry was performed to measure the A values of different wells so as to calculate the killing rate. RESULTS:(1) The expression levels of CD(63), CD(86), and HLA-DR on the membranes of the CpG ODN-pulsed DCs and CpG ODN + C125-pulsed DCs were significantly higher than those of the un-pulsed DCs (all P < 0.01), however, there were no significant differences in the expression of CD(1alpha) among different groups (all P > 0.05). (2) The IL-12 levels in the supernatants of the CpG ODN-pulsed DCs and CpG ODN + C125-pulsed DCs were significantly higher than those of the unpulsed and CA125-pulsed groups (all P < 0.01). (3) MLR showed that the T cell proliferation rates of the T cells sensitized by the CpG ODN-pulsed DCs and CpG ODN + C125-pulsed DCs were both higher than those of the T cells stimulated by the unpulsed and CA125-pulsed groups when the effector: target ratio was 10:1 (all P < 0.01). (4) The killing rates on OVCAR-3 cells of the CTLs sensitized by CpG ODN + CA125-pulsed DCs at the same effector: target ratios were all higher than those of the CTLs sensitized by the CpG ODN-pulsed DCs, CA125-pulsed DCs, and unpulsed DCs (all P < 0.01), the killing activity of the cytotoxic T lymphocytes (CTLs) sensitized by CpG ODN+CA125-pulsed DCs on the OVCAR-3 cells was shown even when the effector: target ratio was as low as 10:1, and then increased along with the increase of the effector: target ratio to the height of 64.9%. CONCLUSION:Capable of inducing immune cytotoxicity on ovarian carcinoma, DCs sensitized by CpG ODN + CA125 may have a great implication on clinical application.

The induction of specific CTL against ovarian cancer by MUC1/Y gene-modified dendritic cells in vitro

Anti-colonic Cancer Effect in Vitro of MUC1 Specific CTLs Induced by MUC1 Core Peptide Tandem Repeats Gene-Modified Dendritic Cells Via Lentiviral Transduction

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.

In vitro anti-tumor effect of cytotoxicity T lymphocytes activated by dendritic cells loaded with freeze-thaw ovarian carcinoma antigen

Expressions of MUC1/Y Gene in Gastrointestinal Cancer and Induction of Anti-Tumor Response by MUC1/Y Gene

[Induction of Specific Cytotoxic T Lymphocytes and Humoral Immune Response by MUC1 DNA Vaccine in Mice].

Research on MUC1 Antigen-specific Cytotoxic T Lymphocytes for Breast Cancer

Induction of specific T lymphocyte and humoral immune responses by MUC1 DNA vaccine and GM-CSF in mice

Anti-gastric carcinoma efficacy of gene modified dendritic cell vaccine recruited by macrophage inflammation protein-1

MUC1/Y plasmids as tumor vaccine in the experimental study of anti-tumor roles in the bladder cancer

[Study of the Cytotoxity Against Human Hepatocellular Carcinoma Cells Induced by the MAGE-1 Gene Modified Dendritic Cells].

In vitro study of anti-tumor immunity of the EWS-FLI1 gene and hGM-CSF gene modified-dendritic cells

Recombinant MUC1-MBP fusion protein combined with CpG2006 vaccine induces antigen-specific CTL responses through cDC1-mediated cross-priming mainly regulated by type I IFN signaling in mice

[Cytotoxicity of Dendritic Cells Pulsed by CpG ODN on Ovarian Carcinoma Cells: in Vitro Experiment with Ovarian Carcinoma Cells].

The immunological investigation for anti-tumor roles of MUC1 vaccine in the bladder cancer

Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine

GENETICALLY MODIFIED DENDRITIC CELLS INDUCED SPECIFIC CYTOTOXITY AGAINST HUMAN HCC CELLS IN VITRO

Generation of CTL Responses Against Pancreatic Cancer in Vitro Using Dendritic Cells Co-Transfected with MUC4 and Survivin RNA.

Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit

Dendritic cells transfected with tumor total RNA induce specific immune responses against hepatocellular carcinoma in vitro